Business Wire - Tuesday May 11, 1999
This presentation can be heard in its entirety beginning on Tuesday, May 11th on the Internet at Wall Street Interview's web site:
http://www.wallstreetinterview.com/Clients/HIV-VAC.htm
According to Dr. Skinner, "Numerous scientists, Universities and other organizations have been working on a vaccine for AIDS over the last 10 years. Most of these studies have developed traditional approaches using old technology that have produced little in the hope for a vaccine to successfully battle the AIDS virus. We have developed a new approach to the AIDS problem through the creation of an intracellular vaccine that is based on a technology proven in clinical trials with both herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines. Not only is the vaccine expected to prevent the disease, but it also may prevent the onset of AIDS in HIV positive patients."
In conjunction with The Russian AIDS Center, the toxicity and immunogenicity phases of vaccine development are being completed. A pilot study using laboratory animals has shown that the intracellular method is a viable approach.
Clinical trials will be underway within nine months, with completion of studies and Government approvals within two to three years.
The United Nations estimates that there are currently 30.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million.
The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.
Contact: HIV-VAC, Inc. K. Jelsing, 702/349-7072
990511
BW990503
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .